PRI-200
Tauopathies
PreclinicalActive
Key Facts
About Priavoid
Priavoid is a clinical-stage biotech pioneering a unique 'detangler' approach to treat neurodegenerative diseases by disassembling neurotoxic protein aggregates. Its proprietary platform generates all-D-peptides, which are orally available, non-immunogenic, and can reach targets in the brain. The pipeline includes a Phase 2 candidate for Alzheimer's (PRI-002), a program for synucleinopathies like Parkinson's (PRI-101), and a preclinical tau-targeting program (PRI-200), positioning the company at the forefront of a novel therapeutic modality for these challenging conditions.
View full company profile